Search results for " titers"
								 					Article
				
				Impact of Media Components on CQAs of Monoclonal Antibodies
								
	The authors review how media components modulate the quality of monoclonal antibody products. 
	By Anurag Rathore, Rajinder Kaur, Dipankar Borgayari 
	
	
	
	
	Recombinant protein products have…								
								 					Article
				
				Fusion Proteins Pose Manufacturability Challenges
								The titers for fusion proteins are generally lower than those for mAbs due to less efficient translation, notes Chamow. 
	Non-human glycans—such as N-glycolylneuraminic acid and alpha-galactose—are …								
								 					Article
				
				Evolution of the Monoclonal Antibody Purification Platform
								For a given amount of mAb product manufactured, the ATPS-based process reduced the annual operating cost by 40% when cell-culture supernatants with mAb titers higher than 2.5 g/L are processed. 
	
…								
								 					Article
				
				Digitalization: The Route to Biopharma 4.0
								
	Industry 4.0, also known as the Fourth Industrial Revolution (4IR), will result in the digital transformation of the manufacturing sector. It is propelled by transformative trends such as the prolif…								
								 					Article
				
				Simple Fed-Batch Process Development for a Knockout Cell Line
								
	CLICK HERE TO READ MORE >>
	
	
	
This workflow improved titers by 500% compared with Chinese hamster ovary cell culture in basal medium.								
								 					Article
				
				Updating Viral Clearance for New Biologic Modalities
								
	Viral clearance processes and guidance must evolve along with newer biotherapeutic modalities. 
	By Feliza Mirasol 
	Ensuring viral clearance (i.e., removal) in downstream purification has becom…								
								 					Article
				
				Improving mAb Manufacturing Productivity by Optimizing Buffer and Media Prep Process Flow
								The increase in titers and the trend toward continuous biomanufacturing will lead to increased demand in buffer volumes and prep times. To address this gap, strategies for improving mAb manufacturing …								
								 					Article
				
				Improving Upstream Predictability
								“We’ve consistently been seeing titers in the range of 4–6 g/L in [monoclonal antibody] mAb fed-batch processing within a chemically defined media environment. This environment, in turn, results in mo…								
								 					Article
				
				Maximizing the Effectiveness of Upstream Bioprocessing Through the Combination of Lab Informatics and Instrumentation
								
	By establishing effective management of data and knowledge, it will be possible to employ advances, such as artificial intelligence and synthetic biology, to their full potential in upstream bioproc…								
								 					Article
				
				Mapping a Route for Cell and Gene Therapy Process Development
								
	 
	
	
	  
	While cell and gene therapies differ in many ways, some of the best practices for process development and validation are similar. 
	
		
		
		  
	
	
		By Cynthia A. Challener 
	
	
…